Tirzepatide Research Overview: GIP/GLP-1 Dual Agonist Mechanism

Tirzepatide is a synthetic 39-amino acid peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It was developed by Eli Lilly and has received regulatory approval in several jurisdictions as a therapeutic agent under the brand name Mounjaro®. As a result, Tirzepatide is among the more clinically characterised compounds available for research purposes, with a substantial published dataset from both preclinical and clinical investigations.

This article provides a research-focused overview of Tirzepatide’s molecular profile, dual receptor mechanism, and the current body of published research. All Bloom Vitality products are supplied strictly for in vitro laboratory and research use only.

Molecular Profile

Tirzepatide is a 39-amino acid linear peptide with a C18 fatty diacid moiety attached via a linker to lysine at position 20. This lipid modification confers extended half-life through albumin binding, enabling once-weekly dosing in clinical settings. The peptide backbone incorporates a GIP-based sequence with strategic amino acid substitutions that confers balanced agonism at both the GIP and GLP-1 receptors.

Dual Receptor Mechanism

• GIP receptor (GIPR) agonism — GIP is an incretin hormone secreted by K-cells in the proximal small intestine in response to nutrient ingestion. GIPR activation promotes insulin secretion in a glucose-dependent manner, modulates glucagon secretion, and is thought to influence adipose tissue metabolism and energy storage.
• GLP-1 receptor (GLP-1R) agonism — GLP-1 is secreted by L-cells in the distal small intestine and colon. GLP-1R activation stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite. GLP-1R agonism is the mechanism shared with compounds such as semaglutide and liraglutide.
• Dual agonism rationale — The combination of GIPR and GLP-1R agonism is proposed to produce complementary and potentially synergistic metabolic effects, particularly with regard to glucose regulation and body weight modulation.

Published Clinical Research

Tirzepatide has been evaluated in the SURPASS clinical trial programme, a series of Phase 3 randomised controlled trials in adults with type 2 diabetes. Key findings from the published literature include:

• Dose-dependent reductions in HbA1c across 5mg, 10mg, and 15mg dose groups
• Significant reductions in body weight, with the 15mg dose producing mean reductions of approximately 11–12 kg in the SURPASS-2 trial
• The SURMOUNT trial programme further investigated Tirzepatide in adults with obesity without diabetes, reporting mean weight reductions of up to 20.9% of body weight at 72 weeks (SURMOUNT-1, 15mg group)

Research Material

Bloom Vitality supplies Tirzepatide as a lyophilised research peptide in two quantities: Tirzepatide 30mg and Tirzepatide 60mg. Both are independently third-party tested for purity and potency.

Batch-specific Certificates of Analysis are available via our Certificates & Documentation page. Our testing methodology is described on the Testing & Quality page. For guidance on reading CoA documentation and HPLC data, see: Peptide Certificate of Analysis: How to Read, Verify and Interpret CoA Documentation.

Investigators investigating related GLP-1/GIP mechanisms may also be interested in our Retatrutide research material — a triple agonist targeting GIP, GLP-1, and glucagon receptors.

For research and laboratory use only. Tirzepatide is a regulated therapeutic compound in many jurisdictions. This article is provided for informational purposes and does not constitute medical advice.